Inhibition of the growth of some hormone dependent tumors by d-Trp6-LH-RH

Andrew V. Schally, Tommie W. Redding, Ana Maria Comaru-Schally

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


We have investigated the effects of chronic administration of D-Trp6-LH-RH on the growth of various hormone dependent tumors in rats and mice. Treatment of male Copenhagen F-1 rats bearing the Dunning R-3327 H prostate adenocarcinoma with 25 μg of D-Trp6-LH-RH bid for 21 days significantly reduced tumor weight and volume as compared to controls. Serum LH, prolactin and testosterone levels in Copenhangen F-1 rats bearing Dunning tumors were significantly decreased after treatment with D-Trp6-LH-RH. Administration of D-Trp6-LH-RH in does of 25 μg/day for 21 days to mice bearing the MXT mammary carcinoma significantly decreased tumor weight and volume. In rats bearing the MT/W9A mammary adenocarcinoma, D-Trp6-LH-RH, at a dose of 25 μg bid for 28 days significantly decreased tumor weight and volume. Administration of D-Trp6-LH-RH in a dose of 25 μg/day, 3-18 days after inoculation with the tumor, inhibited the growth of the prolactin (PRL) and ACTH-secreting pituitary tumor 7315a in female Buffalo rats. In three experiments D-Trp6-LH-RH (30-60 μg/day) decreased tumor weight and/or volume of the Swarm chondrosarcoma. Regression of these hormone-dependent tumors in rats and mice in response to chronic administration of D-Trp6-LH-RH suggests that this compound can be used for treatment of prostate cancer and breast cancer, and also considered for the development of a new endocrine therapy for chondrosarcomas, osteosarcomas, pituitary tumors and other hormone-dependent neoplasias. The demonstration of the successful use of LH-RH agonsits for the palliative management of stage C and D prostate cancer has already shown that this treatment could be employed instead of surgical orchiectomy or estrogen therapy. Preliminary clinical trials suggest that agonists of LH-RH might also be of help in the treatment of breast cancer in premenopausal women.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalMedical Oncology and Tumor Pharmacotherapy
Issue number2
StatePublished - Jun 1 1984
Externally publishedYes


  • Agonist of LH-RH
  • Animal models of prostate cancer
  • Breast cancer
  • Chondrosarcomas
  • Pituitary tumors

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Inhibition of the growth of some hormone dependent tumors by d-Trp<sup>6</sup>-LH-RH'. Together they form a unique fingerprint.

Cite this